Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 89

recruiting
3 973
countries
28
conditions
2 104

1 112 trials match your criteria

Obesity+1

Not recruiting

Study on the Effects of Semaglutide for Weight Management in Children and Adolescents with Obesity or Overweight

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Semaglutide

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ammonium Chloride

Cardiac failure+1

Not recruiting

Study of AZD3427 for Patients with Heart Failure and Pulmonary Hypertension from Left Heart Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AZD3427

Ischaemic stroke

Not recruiting

Study on the Safety and Effectiveness of Tenecteplase for Patients with Acute Ischemic Stroke and Incomplete Reperfusion After Mechanical Thrombectomy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase

Endometrial cancer

Not recruiting

Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide

Malignant melanoma

Not recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide

Hepatic cirrhosis

Not recruiting

Study on Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis and Portal Hypertension

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin

Study on Luspatercept and Epoetin Alfa for Treating Anemia in Patients with Low to Intermediate Risk Myelodysplastic Syndromes Needing Blood Transfusions

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin

Endometrial cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.